TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model

TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model

Abstract Chimeric antigen receptor (CAR) T cell therapy has demonstrated significant clinical efficacy in patients with hematologic cancers. However, long-term follow-up studies indicate that only 50% of patients remain in complete remission after three years. To overcome these limitations, we inves...

Full description

Saved in:
Bibliographic Details
Main Authors: Yeongrin Kim, Moonjung Jeun, Heung Kyoung Lee, Ji U Choi, Simon Park, Chi Hoon Park
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Experimental Hematology & Oncology
Subjects:
CAR T cell
TET2
shRNA
Cancer
Immunotherapy
CAR T cell therapy
Online Access:https://doi.org/10.1186/s40164-025-00609-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items